Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
30 results
D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma
D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)
D1.152 - Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units
D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites
D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix
D1.155 - Alterations in B cell memory induced by house dust mite allergen immunotherapy
D1.156 - Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients
D1.157 - Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis
D1.159 - The successful resolve of nasal polyps in patient with dupilumab treatment
D3.265 - Biphasic anaphylaxis secondary to polyethylene glycol in a pediatric patient: a case report
D3.268 - Chronic Allergen Exposure Induces Accumulation of IgE Plasma Cells in the Lung, Leading to Local IgE Antibody Production
D3.269 - Drug-Induced Anaphylaxis in Children: A Comparative Analysis of Inpatient vs. Outpatient Settings
D3.270 - A novel workflow for cell metabolomics: impact of anaphylaxis in a human endothelial system
D3.272 - Safety and Efficacy of Vancomycin and Other Antimicrobial Drug Desensitization in Pediatric Patients
D3.273 - Assessing Anaphylaxis in COVID-19 vaccines: Application of amended Brighton Collaboration Criteria
D3.274 - Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria
D3.275 - Anaphylaxis caused by polyhexanide
D3.276 - Acalabrutinib as premedication in platinum agents desensitization protocols: a case series supporting its role in enhancing tolerance with a repeatible efficacity
D3.277 - Features of severe anaphylaxis in children, data from the Moscow Pediatric Register
D3.290 - Manifestations of allergic skin lesions in the early childhood and adult population: Epidemiological manifestations of diseases
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download